Calithera Biosciences, Inc.
CALAOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$1462
P/E Ratio—
52W High$0.002
52W Low$0.0001
Calithera Biosciences, Inc. (CALA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CALA · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2023Report Date: Mar 30, 2023EPS Actual
-$1.42
Est. -$1.49 · +4.7%
Revenue
—
Est. $0.00B
Fiscal Period
Q1 FY2023
FY ends December
Report Date
Mar 30, 2023
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CALA reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$4.80 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | May 29, 2026 | — | — | — | — | — | — |
| ◌ Q2 FY2026 | May 13, 2026 | -$4.80 | — | — | — | — | — |
| ◌ Q1 FY2026 | Feb 25, 2026 | -$5.52 | — | — | — | — | — |
| ◌ Q1 FY2024 | Mar 29, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 13, 2023 | — | — | — | — | — | — |
| ◌ Q3 FY2023 | Aug 23, 2023 | — | — | — | — | — | — |
| ▲ Q1 FY2023 | Mar 30, 2023 | -$1.49 | -$1.42 | +4.7% | — | $0.00B | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$4.80
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 29, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026
EPS Actual
—
EPS Est.
-$4.80
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 25, 2026
EPS Actual
—
EPS Est.
-$5.52
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 29, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 13, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 23, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Mar 30, 2023Beat
EPS Actual
-$1.42
EPS Est.
-$1.49
EPS Surpr.
+4.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2030 | $-3.03 | $-3.03 | $-3.03 | 1 |
| Q2 FY2030 | $-3.03 | $-3.03 | $-3.03 | 1 |
| Q1 FY2030 | $-3.03 | $-3.03 | $-3.03 | 1 |
| Q4 FY2029 | $-3.03 | $-3.03 | $-3.03 | 1 |
| Q3 FY2029 | $-3.03 | $-3.03 | $-3.03 | 1 |
| Q2 FY2029 | $-3.03 | $-3.03 | $-3.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2030 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2030 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2023 | Mar 30, 2023 | +4.7% | $0.06 | $0.04 | -27.09% |
| — Q4 FY2022 | Dec 31, 2022 | — | $3.26 | $3.08 | -5.52% |
| ▼ Q4 FY2022 | Nov 14, 2022 | -1.0% | $2.61 | $2.82 | +8.05% |
| ▲ Q3 FY2022 | Aug 15, 2022 | +41.1% | $4.11 | $4.14 | +0.61% |
| ▼ Q2 FY2022 | May 10, 2022 | -5.9% | $4.01 | $4.09 | +2.04% |
Q1 FY2023-27.09%
Report Date
Mar 30, 2023
EPS Beat/Miss
+4.7%
Price Before
$0.06
Price After
$0.04
Q4 FY2022-5.52%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$3.26
Price After
$3.08
Q4 FY2022+8.05%
Report Date
Nov 14, 2022
EPS Beat/Miss
-1.0%
Price Before
$2.61
Price After
$2.82
Q3 FY2022+0.61%
Report Date
Aug 15, 2022
EPS Beat/Miss
+41.1%
Price Before
$4.11
Price After
$4.14
Q2 FY2022+2.04%
Report Date
May 10, 2022
EPS Beat/Miss
-5.9%
Price Before
$4.01
Price After
$4.09
Avg Beat Reaction-13.24%
Avg Miss Reaction+5.04%
Beat Rate2 / 5 quarters
Largest Move-27.09% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CALA ends December
Calithera Biosciences, Inc. (CALA) most recently reported earnings on March 30, 2023 for Q1 FY2023, posting EPS of $-1.42 — beating the analyst consensus of $-1.49 by +4.7%. The next CALA earnings date is expected around September 1, 2026.
Each quarter, investors track CALA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CALA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CALA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CALA earnings · 5 questionsCalithera Biosciences, Inc.'s next earnings report is expected around September 1, 2026. CALA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CALA historically reports after market close (AMC).
CALA earnings datewhen is CALA earningsCALA next earnings datewhen does CALA report earningsCALA earnings calendar
▸ Source: FMP · Calithera Biosciences, Inc. SEC filings · US GAAP · Calithera Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026